Religare Enterprises Limited reported a narrowed standalone net loss of ₹96.2 crore for the quarter ended June 30, 2026, compared to a loss of ₹123.6 crore in the previous quarter. The improvement coincided with a rise in total income to ₹438.2 crore, up from ₹335.6 crore in the prior quarter.

The board approved the unaudited standalone financial results on August 12, 2026, following a limited review by statutory auditors J C Bhalla & Co. The company’s total comprehensive income stood at a loss of ₹96.2 crore for the quarter.

Financial Performance

Revenue from operations increased to ₹251.7 crore from ₹172.5 crore in the previous quarter. Interest income rose to ₹166.5 crore from ₹126.7 crore, while net gain on fair value changes surged to ₹30.4 crore from ₹0.4 crore. Other operating income also grew to ₹54.8 crore from ₹45.3 crore.

Total expenses declined to ₹1,400.1 crore from ₹1,572.1 crore. Employee benefits expense increased significantly to ₹927.5 crore from ₹462.1 crore, while other expenses dropped sharply to ₹395.4 crore from ₹1,022.5 crore. Finance costs remained relatively stable at ₹22.8 crore, up slightly from ₹19.3 crore.

Capital Raise and Investments

During the quarter, Religare Enterprises converted share warrants into equity shares, receiving proceeds of ₹1,470.5 lakh. This conversion involved 83,43,263 shares allotted at a price of ₹235 per share. Consequently, the paid-up equity capital increased to ₹3,412.3 crore divided into 34,12,33,742 equity shares.

The company also subscribed to a rights issue amounting to ₹1,196.9 lakh in its subsidiary, Care Health Insurance Ltd (CHIL). Cash and cash equivalents rose to ₹298.3 lakh from ₹210.0 lakh at the end of the previous quarter.

What the Numbers Show

The narrowing of the net loss was primarily driven by a significant reduction in other expenses rather than operational revenue growth alone. While revenue from operations grew by nearly 46%, employee benefits expense more than doubled, indicating a shift in cost structure. The substantial drop in other expenses—from over ₹1,000 crore to under ₹400 crore—was the key factor in reducing the overall loss burden for the quarter.

Regulatory and Legal Updates

The company continues to face ongoing legal proceedings. It remains barred from declaring dividends as per an RBI letter issued in December 2019. Additionally, the Reserve Bank of India did not accede to the company’s request regarding a proposed demerger scheme with Religare Finvest Limited, issuing a communication on August 6, 2026. The company plans to engage further with the regulator to provide necessary clarifications.

Income tax litigation remains pending before the Income Tax Appellant Tribunal (ITAT). A rectification order reduced the tax demand to ₹1,085.3 lakh for the assessment year 2017-18. The company has obtained an interim stay on the recovery of this demand and views the chances of a favorable outcome as high.

The Nomination and Remuneration Committee of Religare Enterprises approved the grant of 13,195 stock options to eligible employees under the company’s Employee Stock Option Plan 2019 during a meeting held on August 12, 2026. This equity incentive move aligns employee interests with shareholder value creation, as the options carry an exercise price of ₹227.35 per share and vest over a five-year period.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scheme itself conforms to the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, having received prior approval from both the Board of Directors and shareholders. Each stock option is convertible into one equity share with a face value of ₹10.

Key Terms of the Grant

The structural details of the option grant are outlined below:

Under the vesting schedule, 2,639 options will vest annually for five consecutive years, starting one year after the grant date. Employees must exercise their vested options no later than eight years from the respective vesting dates. As of the filing date, no options have been exercised, lapsed, or cancelled, and there have been no variations to the terms of the options.

Impact on Shareholder Metrics

Since the options remain unexercised, they do not currently impact the diluted earnings per share (EPS) or the total number of outstanding shares. The potential dilution will only materialize if and when employees exercise their rights to convert the options into equity shares. The fixed exercise price of ₹227.35 serves as the baseline cost for employees to acquire these shares, reflecting the valuation parameters set by the committee at the time of grant.

The company’s Group General Counsel & Group Chief Compliance Officer, Babu Rao P., certified the disclosure to the National Stock Exchange of India Ltd. and BSE Limited. The filing ensures transparency regarding the equity compensation structure and its adherence to regulatory frameworks governing share-based benefits in India.